New combo before liver surgery aims to stop cancer return

NCT ID NCT07239245

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining a liver-directed procedure (TACE) with two drugs—atezolizumab (immunotherapy) and bevacizumab (anti-angiogenic)—given before surgery can improve outcomes for patients with liver cancer at high risk of recurrence. About 30 adults with resectable hepatocellular carcinoma and high-risk features will receive the combination, then undergo surgery. The main goal is to see how many patients have no remaining cancer cells in the removed tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs) plus transarterial chemoembolization (TACE) procedure
What this could lead to: If successful, this combination could become a standard neoadjuvant treatment to shrink liver tumors before surgery and lower the chance of cancer coming back.
What could go wrong: This is a small, early-phase trial with only 30 participants and no comparison group. The added drugs may cause side effects like bleeding or immune reactions, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Science
RECRUITING

Beijing, Beijing Municipality, 100021, China
Henan Cancer Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, China
Shanxi Cancer Hospital
NOT_YET_RECRUITING

Taiyuan, Shanxi, China
The First Hospital of China Medical University
NOT_YET_RECRUITING

Shenyang, Liaoning, China